Trial Profile
Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cisplatin; Gemcitabine
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.